Investors in Master Drilling Group (JSE:MDI) have seen splendid returns of 212% over the past five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. One great example is Master Drilling Group Limited (JSE:MDI) which saw its share price drive 170% higher over five years. On top of that, the share price is up 20% in about a quarter.
Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
During five years of share price growth, Master Drilling Group achieved compound earnings per share (EPS) growth of 2.7% per year. We do note that extraordinary items have impacted its earnings history. This EPS growth is lower than the 22% average annual increase in the share price. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth.
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
Dive deeper into Master Drilling Group's key metrics by checking this interactive graph of Master Drilling Group's earnings, revenue and cash flow.
It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Master Drilling Group's TSR for the last 5 years was 212%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.
It's nice to see that Master Drilling Group shareholders have received a total shareholder return of 36% over the last year. Of course, that includes the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 26% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Master Drilling Group is showing 2 warning signs in our investment analysis , you should know about...
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South African exchanges.
—
Investing narratives with Fair Values
Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor
Fair Value Estimated: A$2.42 · 0.1% Overvalued
Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor
Fair Value Estimated: €78.41 · 0.1% Overvalued
Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor
Fair Value Estimated: $325.55 · 0.6% Undervalued
View more featured narratives
—
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Public companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%
The considerable ownership by public companies in Gyre Therapeutics indicates that they collectively have a greater say in management and business strategy 71% of the company is held by a single shareholder (GNI Group Ltd.) Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. If you want to know who really controls Gyre Therapeutics, Inc. (NASDAQ:GYRE), then you'll have to look at the makeup of its share registry. With 71% stake, public companies possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Individual investors, on the other hand, account for 19% of the company's stockholders. In the chart below, we zoom in on the different ownership groups of Gyre Therapeutics. See our latest analysis for Gyre Therapeutics Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Institutions have a very small stake in Gyre Therapeutics. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too. We note that hedge funds don't have a meaningful investment in Gyre Therapeutics. GNI Group Ltd. is currently the largest shareholder, with 71% of shares outstanding. This implies that they have majority interest control of the future of the company. Meanwhile, the second and third largest shareholders, hold 3.1% and 3.1%, of the shares outstanding, respectively. Songjiang Ma, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in Gyre Therapeutics, Inc.. In their own names, insiders own US$53m worth of stock in the US$755m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a 19% stake in Gyre Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. It appears to us that public companies own 71% of Gyre Therapeutics. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. It's always worth thinking about the different groups who own shares in a company. But to understand Gyre Therapeutics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Gyre Therapeutics (of which 1 makes us a bit uncomfortable!) you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
Here's How Much a $30,000 Investment in the Nasdaq 100 Today Could Be Worth in 30 Years
Investors can gain exposure to top growth stocks like Amazon and Nvidia by investing in the Invesco QQQ Trust. The exchange-traded fund has averaged a compound annual return of more than 18% over the past decade. Investing $30,000 into the fund today could potentially result in your portfolio being worth over $1 million in the future. 10 stocks we like better than Invesco QQQ Trust › Growth stocks can generate returns far superior to those of value stocks or dividend stocks in the long run. These are the types of companies that investors are drawn to because if they're growing, they are expanding their operations and likely innovating and potentially diversifying along the way. Names like Amazon and Nvidia are two exceptional examples. Over the past 20 years, the former has produced returns of 12,000% while the latter is up more than 60,000%. Investing $30,000 into either one of the stocks back then would have made you millions of dollars. Picking the next big growth stock is easier said than done. But the good news is that you don't have to pick the next Amazon or Nvidia to achieve great results. The Invesco QQQ Trust (NASDAQ: QQQ) is an exchange-traded fund (ETF) that will give you exposure to the top 100 nonfinancial stocks in the Nasdaq exchange, also known as the Nasdaq 100. Amazon, Nvidia, and many other top tech names are included in that list. Here's how a $30,000 investment in the fund might grow over the long haul. The best growth stocks in the world are often found on the Nasdaq. And by targeting the top 100 nonfinancial companies, you won't have to worry about keeping an eye on which growth stocks to buy. The Invesco fund will adjust its holdings over time, removing poor-performing stocks and replacing them with rising stars. Some of the top holdings in the ETF today include Costco Wholesale, Netflix, and Broadcom. While it is a tech-heavy fund (tech stocks account for 57% of its holdings), about 20% of the portfolio is also in consumer discretionary stocks, followed by smaller positions in other sectors. And more than 97% of the holdings are U.S. stocks, which can minimize your exposure to international markets. It's little surprise, with so much focus on growth, that the Invesco QQQ Trust widely outperformed the S&P 500 over the past decade. At 430%, it has averaged a compound annual growth rate of more than 18%. As impressive as the Invesco ETF's returns have been over the past decade, they've also been skewed in recent years by a flurry of tech spending, which may not persist in the very long term. That's why it may be a good idea to scale back expectations of what its future returns may look like. Rather than 18%, perhaps closer to the long-run average of 10% for the S&P 500 might be appropriate. The table below shows what a $30,000 investment might grow to at varying rates after 30-plus years. Years 9% Growth 10% Growth 11% Growth 12% Growth 13% Growth 30 $398,030 $523,482 $686,769 $898,798 $1,173,477 31 $433,853 $575,830 $762,313 $1,006,653 $1,326,029 32 $472,900 $633,413 $846,168 $1,127,452 $1,498,413 33 $515,461 $696,755 $939,246 $1,262,746 $1,693,206 34 $561,852 $766,430 $1,042,564 $1,414,276 $1,913,323 35 $612,419 $843,073 $1,157,246 $1,583,989 $2,162,055 Table and calculations by author. There's no way to know what growth rate the Invesco ETF will end up averaging, especially when you're looking at such a long period of time. But the big takeaway is that with the effects of compounding, you can potentially build up a significant portfolio simply by putting $30,000 into a top growth fund like the Invesco QQQ Trust and letting it sit. It's a perfect example of a buy-and-forget type of investment. Before you buy stock in Invesco QQQ Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Costco Wholesale, Netflix, and Nvidia. The Motley Fool recommends Broadcom and Nasdaq. The Motley Fool has a disclosure policy. Here's How Much a $30,000 Investment in the Nasdaq 100 Today Could Be Worth in 30 Years was originally published by The Motley Fool
Yahoo
33 minutes ago
- Yahoo
CarMax shares surge on strong Q1 earnings beat
-- CarMax Inc. shares jumped 7.2% in premarket trading on Friday after the used car retailer reported first-quarter earnings that easily topped Wall Street expectations, driven by higher sales volumes and strong profit margins. The company reported earnings per share of $1.38 for the quarter ended May 31, beating analyst estimates of $1.19. Revenue rose 6.1% YoY to $7.55 billion, slightly above the $7.54 billion consensus forecast. Retail used vehicle unit sales increased 9% YoY to 230,210, with comparable store sales up 8.1%. Total gross profit climbed 12.8% to $893.6 million, helped by record high gross profit per retail used unit of $2,407. "We delivered our fourth consecutive quarter of positive retail comps and double-digit year-over-year earnings per share growth," said Bill Nash, CarMax (NYSE:KMX)'s president and CEO. "These results highlight the strength of our earnings growth model, which is underpinned by our best-in-class omni-channel experience, the diversity of our business, and our sharp focus on execution." The company's strong performance came despite ongoing economic uncertainty. CarMax Auto Finance (CAF) income decreased 3.6% to $141.7 million as higher provisions for loan losses offset growth in CAF's net interest margin. CarMax accelerated its share repurchase program, buying back $199.8 million worth of stock during the quarter. The company had $1.74 billion remaining on its repurchase authorization as of May 31. Related articles CarMax shares surge on strong Q1 earnings beat The Middle East crises could end up offering a good buying opportunity: Barclays EXCLUSIVE: Dot Ai completes merger with SPAC ShoulderUp
